Molecularly targeted therapies for glioma

Ryuya Yamanaka, Hideyuki Saya

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.

Original languageEnglish
Pages (from-to)717-729
Number of pages13
JournalAnnals of Neurology
Volume66
Issue number6
DOIs
Publication statusPublished - 2009 Dec

Fingerprint

Glioma
Pharmaceutical Preparations
Therapeutics
Neoplasms
Cell Surface Receptors
Proteasome Endopeptidase Complex
Ubiquitin
Heat-Shock Proteins
Signal Transduction
Phenotype
Genes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Molecularly targeted therapies for glioma. / Yamanaka, Ryuya; Saya, Hideyuki.

In: Annals of Neurology, Vol. 66, No. 6, 12.2009, p. 717-729.

Research output: Contribution to journalArticle

Yamanaka, Ryuya ; Saya, Hideyuki. / Molecularly targeted therapies for glioma. In: Annals of Neurology. 2009 ; Vol. 66, No. 6. pp. 717-729.
@article{90aa5367582e4133ab4a30dfde2ac629,
title = "Molecularly targeted therapies for glioma",
abstract = "Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.",
author = "Ryuya Yamanaka and Hideyuki Saya",
year = "2009",
month = "12",
doi = "10.1002/ana.21793",
language = "English",
volume = "66",
pages = "717--729",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Molecularly targeted therapies for glioma

AU - Yamanaka, Ryuya

AU - Saya, Hideyuki

PY - 2009/12

Y1 - 2009/12

N2 - Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.

AB - Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=73549096412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549096412&partnerID=8YFLogxK

U2 - 10.1002/ana.21793

DO - 10.1002/ana.21793

M3 - Article

C2 - 20035507

AN - SCOPUS:73549096412

VL - 66

SP - 717

EP - 729

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -